Kyoto University and BostonGene have launched a multicentre Phase II trial that pairs immune checkpoint inhibitors with photodynamic therapy to treat advanced gastrointestinal cancers.
Trial design and partnership details
The investigator‑initiated study is being led by Dr. Manabu Muto of Kyoto University and receives financial backing from Meiji Seika Pharma Co., Ltd. BostonGene will apply its AI‑driven multimodal analytics platform to combine genomic, transcriptomic, immune and clinical data collected during the trial.
By integrating these data streams, the collaboration hopes to pinpoint molecular signatures and immune‑response patterns that correlate with treatment success or resistance. The goal is to build a framework that can guide future patient stratification and the development of combination therapies.
Scientific rationale and expected outcomes
Photodynamic therapy (PDT) activates a light‑sensitive drug to destroy tumor cells, while immune checkpoint inhibitors (ICI) release the brakes on the immune system. Muto said the combination aims to boost anti‑tumor responses in patients who have few treatment options.
“Applying BostonGene’s AI‑driven molecular and immune system profiling capabilities allows us to better characterise the tumor microenvironment and identify the biological features associated with durable clinical benefit,” he explained.
BostonGene Japan president Yukimasa Shiotsu added that incorporating AI‑powered multi‑omics analysis into clinical development is essential for advancing next‑generation oncology therapeutics. “This partnership allows us to better understand the biological mechanisms underlying response to ICI and PDT combination therapy and identify the patient populations most likely to benefit from these approaches,” he said.
Related: Sunway Medical supports national health screening drive
The trial’s findings are expected to inform future study designs, support biomarker‑driven patient selection, and aid the creation of new combination immunotherapy strategies.
From a broader view, using AI to sift through complex molecular data could shorten the time it takes to match patients with the right therapy, a persistent challenge in oncology. If the trial identifies reliable biomarkers, it may set a precedent for how academic‑industry collaborations approach precision medicine, especially in cancers where conventional treatments have limited impact.
Enrollment targets have not been disclosed, but the multicentre nature of the study suggests participation across several hospitals in Japan. Data collection will follow standard protocols for Phase II trials, with periodic safety and efficacy assessments.
Should the combination prove effective, it could expand the therapeutic arsenal for gastrointestinal malignancies, a group that includes cancers of the stomach, pancreas and colon, which collectively account for a substantial share of cancer deaths worldwide.
As the trial progresses, both institutions plan to share interim results with the scientific community, potentially via conference presentations or peer‑reviewed publications. The collaboration shows a growing trend where AI tools are embedded early in drug development pipelines to accelerate discovery and improve patient outcomes.